--- title: "Weekly Recap | Corteva -4.51%, most brokers rate it buy" type: "News" locale: "en" url: "https://longbridge.com/en/news/298800850.md" description: "Corteva (CTVA) fell 4.51% this week to close at $83.90, while the S&P 500 slipped 0.8%, leaving the stock about 3.71 percentage points behind the benchmark. Across the four trading sessions, the price faded after a strong start: Tuesday opened at $88.25 and touched the week’s high of $89.13, then drifted lower over the next three days, with Friday dipping to $82.485 before finishing at $83.90. The weekly range was 7.53%, and average daily volume of 4.43m shares ran 12." datetime: "2026-09-12T08:01:50.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/298800850.md) - [en](https://longbridge.com/en/news/298800850.md) - [zh-HK](https://longbridge.com/zh-HK/news/298800850.md) generator: "portal-rs" --- # Weekly Recap | Corteva -4.51%, most brokers rate it buy ## The Week Corteva (CTVA) fell 4.51% this week to close at $83.90, while the S&P 500 slipped 0.8%, leaving the stock about 3.71 percentage points behind the benchmark. Across the four trading sessions, the price faded after a strong start: Tuesday opened at $88.25 and touched the week’s high of $89.13, then drifted lower over the next three days, with Friday dipping to $82.485 before finishing at $83.90. The weekly range was 7.53%, and average daily volume of 4.43m shares ran 12.35% above the 60-day median of 3.95m. ## Key Events The most tangible company development was the definitive agreement with Globachem to form a joint venture aimed at advancing and commercialising new formulated crop protection solutions. Elsewhere, commentary around the corn technology roadmap suggested the bull case for Corteva could change, though no specific product timeline was confirmed. On the regulatory front, Corteva, Chemours and DuPont reached an agreement to resolve PFAS-related claims in North Carolina, while DuPont disclosed a probable loss of about $125 million in Q2 2026 in an SEC filing. Headline coverage also noted the stock underperformed competitors on Tuesday and outperformed them on Thursday despite closing lower. ## Analyst Ratings A total of 22 brokers cover the stock: 11 rate it buy, 3 overweight, 8 hold, and none underweight or sell. The consensus rating is buy, with a consensus target of $92.10, about 9.77% above this week’s close of $83.90. Targets range from $78 to $103, a fairly wide spread of roughly $25 that points to divided views on the stock’s near-term path. Among 11 names in the fertilisers and agrochemicals industry, Corteva ranks second by rating strength. ## The Week Ahead Macro data dominates the calendar in the coming week: the New York Fed manufacturing index on Tuesday, followed by retail sales, retail sales ex-autos, import prices and the NAHB housing market index on Wednesday. Corteva itself has no scheduled earnings release on the calendar, so the more stock-specific threads to watch are any further details on the PFAS settlement and any company response to the corn technology roadmap discussion. ## In Short The pullback this week sat alongside a mix of corporate progress and legal resolution: most brokers rate the stock buy and the consensus target sits nearly 10% above the close, yet the corn roadmap narrative has introduced uncertainty into the bull case. Valuation is not cheap, with a P/E of around 55.48 and P/B near 2.22; in the latest session, large and medium orders were net buyers while small orders saw net selling. The key question ahead is whether Corteva clarifies its position on the corn technology roadmap, and whether next week’s retail sales and manufacturing data give cyclical names a fresh reason to reprice. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [CTVA.US](https://longbridge.com/en/quote/CTVA.US.md) ## Related News & Research - [Learn Why The Bull Case For Corteva (CTVA) Could Change Following Corn Technology Roadmap](https://longbridge.com/en/news/298362778.md) - [Corteva spins off seed unit as Vylor in October 1 share distribution](https://longbridge.com/en/news/298914348.md) - [CTVA: Targeting $11.2–$11.9B sales and 30% EBITDA margin by 2029, fueled by innovation and licensing](https://longbridge.com/en/news/299051102.md) - [CTVA: Transforming into an IP-driven platform, Vylor targets $2B licensing revenue and 30% margins by 2029](https://longbridge.com/en/news/299086325.md) - [Corteva (NYSE:CTVA) Earns "Outperform" Rating from Royal Bank Of Canada](https://longbridge.com/en/news/299187615.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**